With respect to South Korea, Novartis fixed specific properly-publicized allegations that it experienced made improper payments to HCPs in South Korea by spherical tables and third-bash healthcare journals. Novartis Korea allegedly transmitted improper honoraria to HCPs for spherical tables by means of clinical journals to stop compliance scrutiny,